Bausch Health
About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Employees: 20,700
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
1% more funds holding
Funds holding: 224 [Q4 2024] → 226 (+2) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 66
2.65% less ownership
Funds ownership: 68.91% [Q4 2024] → 66.26% (-2.65%) [Q1 2025]
23% less capital invested
Capital invested by funds: $1.99B [Q4 2024] → $1.54B (-$455M) [Q1 2025]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]
73% less call options, than puts
Call options by funds: $19.6M | Put options by funds: $71.3M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
51%
upside
Avg. target
$10
51%
upside
High target
$10
51%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
RBC Capital Douglas Miehm | 51%upside $10 | Sector Perform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 11 articles about BHC published over the past 30 days
Neutral
Accesswire
6 hours ago
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government's Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations and that of the Correctional Service of Canada (CSC). CABTREO is a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.
Neutral
Accesswire
6 hours ago
Bausch Health Appoints New Chief Accounting Officer
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective Monday, July 14. Steven brings extensive experience in financial transformation, mergers and acquisitions, and operational execution.
Neutral
Accesswire
1 day ago
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government's Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations and that of the Correctional Service of Canada (CSC). CABTREO is a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.
Neutral
Accesswire
3 days ago
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced its new direct-to-consumer (DTC) "I Wish I Knew" campaign for Xifaxan® (rifaximin), the first and only medicine FDA approved for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Designed to raise awareness about OHE and the role of Xifaxan, "I Wish I Knew" seeks to educate and empower patients and caregivers to take proactive steps in managing their liver disease.
Neutral
Accesswire
1 week ago
Bausch Health to Announce Second Quarter 2025 Results on July 30
LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Neutral
Business Wire
2 weeks ago
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”). In addition, the compa.
Positive
24/7 Wall Street
2 weeks ago
Five Popular Stocks Insiders Have Been Aggressively Buying
We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.
Positive
Barrons
2 weeks ago
A Billionaire Trump Supporter Is Buying These Two Stocks
John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.
Neutral
24/7 Wall Street
3 weeks ago
Insiders Make Huge Buys in Gold Miners and More
In the past week or so, a couple of gold-mining stocks attracted the attention of insider buyers.
Positive
Market Watch
3 weeks ago
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares
Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.
Charts implemented using Lightweight Charts™